Algernon Pharmaceuticals Inc.
AGN
CNSX
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.21M | 1.22M | 1.54M | 1.74M | 2.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.59M | 1.70M | 2.14M | 2.60M | 2.75M |
| Operating Income | -1.59M | -1.70M | -2.14M | -2.60M | -2.75M |
| Income Before Tax | -272.30K | -377.30K | -1.97M | -3.86M | -4.03M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.27 | -0.38 | -1.97 | -3.86 | -4.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -272.30K | -377.30K | -1.97M | -3.86M | -4.03M |
| EBIT | -1.59M | -1.70M | -2.14M | -2.60M | -2.75M |
| EBITDA | -1.57M | -1.68M | -2.11M | -2.56M | -2.72M |
| EPS Basic | -0.01 | -0.03 | -0.08 | -0.20 | -0.26 |
| Normalized Basic EPS | -0.05 | -0.05 | -0.02 | -0.10 | -0.14 |
| EPS Diluted | -0.02 | -0.03 | -0.08 | -0.20 | -0.26 |
| Normalized Diluted EPS | -0.05 | -0.06 | -0.02 | -0.10 | -0.14 |
| Average Basic Shares Outstanding | 91.69M | 80.16M | 87.12M | 76.44M | 66.83M |
| Average Diluted Shares Outstanding | 92.19M | 80.67M | 87.62M | 76.44M | 66.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |